Navigation Links
GeoVax Labs, Inc. Announces First Quarter Financial Results
Date:5/7/2009

ether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.

FINANCIAL TABLES FOLLOW


                               GEOVAX LABS, INC.
           Condensed Consolidated Statements of Operations Information
                (amounts in thousands, except per share data)

                                            Three Months Ended
                                                 March 31,
                                             2009        2008
      Revenues
         Grant Revenue                        $710        $600

      Operating expenses:
         Research and development              857         603
         General and administrative            724         706
                                             1,581       1,309

      Other income (expense)
         Interest income                         9          27
                                                 9          27

      Net loss                               $(862)      $(683)

      Loss per common share                 $(0.00)     $(0.00)



                               GEOVAX LABS, INC.
                       Condense
'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
9. GeoVax to Present at the BIO CEO & Investor Conference 2009
10. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
11. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 While ... in health services research for a relatively long ... in interest regarding the use of these ‘big ... conditions. , By combining today’s powerful computer technology ... digital era, ‘big data’ holds significant promise for ...
(Date:7/30/2014)... With the accelerated aging of ... expenditure as well as the improved medical care ... reagent industry has been developing quickly, especially in ... Chinese in vitro diagnostics market size reached RMB22.98 ... vitro diagnostic reagents. , Read complete report ...
(Date:7/30/2014)... AZ (PRWEB) July 30, 2014 ... State-of-the-art facility and complementary therapies brings comprehensive cancer ... foot, state-of-the-art Yuma Regional Cancer Center has officially ... 2012, the program includes services such as open, ... massage therapy, American Cancer Society Resource Center, hematology, ...
(Date:7/30/2014)...   Epic Sciences, Inc. ("Epic"), a private ... personalize and advance the treatment and management of cancer, ... as chairman of Epic,s board of directors. Mr. ... (formerly Invitrogen). Mr. Lucier joins Epic,s board of directors ... cell analysis platform with special focus on the development ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3
... announces that a new market research report is ... Oxide: 2010 World Market Outlook And Forecast ... report analyzes worldwide markets for Propylene oxide, including ... provides the most complete and current analytical account ...
... (Nasdaq: MYL ) today announced its financial results for ... its financial guidance for 2011.   Financial Results ... ended December 31, 2010 compared to $0.33 for the same prior ... of $1.61 for the year ended December 31, 2010 compared to ...
... in German . , They have been used ... now they are making rapid inroads in high performance applications: ... phones and digital cameras. The automotive industry, for instance, has ... using them in driver assistance systems from parking aids ...
Cached Biology Technology:Reportlinker Adds Propylene Oxide: 2010 World Market Outlook and Forecast 2Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 2Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 3Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 4Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 5Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 6Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 7Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 8Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 9Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 10Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 11Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 12Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 13Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 14Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 15Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 16Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 17Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year 18UV-transparent coating for image sensors 2
(Date:7/30/2014)... NexID Biometrics , a leading ... for the biometric authentication industry, has recently joined ... authentication with standards for strong authentication. According to ... to join FIDO Alliance stems from NexID,s mission ... We believe the FIDO Alliance is a key ...
(Date:7/30/2014)... colors, nature had already perfected the process think ... example. Now scientists are tapping into those secrets to ... plastics. Their paper on using structure or the ... to produce color appears in the ACS journal ... and colleagues point out that currently, plastic manufacturers add ...
(Date:7/30/2014)... from Bjorn Brembs, professor of neurogenetics at the Institute ... figure allowing readers and reviewers to run the underlying ... important leap forward for scientific publishing, by demonstrating a ... scholarly output. , Figure 3 in fact doesn,t really ... to F1000Research , and the figure is generated ...
Breaking Biology News(10 mins):NexID Biometrics Joins the FIDO Alliance 2F1000Research brings static research figures to life 2
... studies reveal that voting decisions are more associated ... a politician,s appearance than to positive ones, says ... of Technology (Caltech), Scripps College, Princeton University, and ... particularly true when voters have little or no ...
... beware. Chances are your male partner is on your ... even when you have kept to the straight and ... constant vigilance, women may be better than men at ... in Richmond and colleagues gave 203 young heterosexual couples ...
... sustainability expert Deane Evans will provide an introduction to the basics of ... seminar, open to the public, at NJIT. The talk, set ... a review of the status of the NJ schools, construction program. ... Evans, a registered architect, is executive director ...
Cached Biology News:Caltech-led researchers find negative cues from appearance alone matter for real elections 2Caltech-led researchers find negative cues from appearance alone matter for real elections 3Caltech-led researchers find negative cues from appearance alone matter for real elections 4Men are better at detecting infidelities 2
... Polymerase is ideal for high-fidelity amplification ... such as cloning and mutagenesis. ... proprietary enzyme preparation containing recombinant DNA ... (3'Cut Site5' exonuclease) activity. Platinum ...
... precision beveling of micropipette tips ... unique abrasive plate drive system ... control of the beveling process. ... rapidly and produces consistent tip ...
... mM sodium phosphate buffer, pH 6.5. Cathepsin ... a major lysosomal aspartyl protease in mammalian ... Overexpression of cathepsin D in human breast ... relapse and metastasis. Cathepsin D degrades extracellular ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
Biology Products: